LivaNova (NASDAQ:LIVN) Hits New 1-Year High – Time to Buy?

LivaNova PLC (NASDAQ:LIVN) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $80.96 and last traded at $80.4150, with a volume of 11296 shares changing hands. The stock had previously closed at $79.39.

Analysts Set New Price Targets

A number of analysts have issued reports on LIVN shares. Barclays raised their target price on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Needham & Company LLC raised their target price on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Mizuho raised their target price on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Finally, Stifel Nicolaus set a $80.00 price objective on LivaNova in a research report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $79.38.

LivaNova Price Performance

The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The firm has a market cap of $4.40 billion, a P/E ratio of 41.11 and a beta of 0.88. The company has a 50-day moving average of $69.08 and a 200 day moving average of $65.81.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts anticipate that LivaNova PLC will post 3.73 EPS for the current year.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.35% of the stock is owned by company insiders.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hantz Financial Services Inc. lifted its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares during the period. State of Wyoming acquired a new stake in LivaNova during the 2nd quarter valued at $31,000. EverSource Wealth Advisors LLC increased its holdings in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares in the last quarter. Quarry LP acquired a new stake in LivaNova during the 3rd quarter valued at $36,000. Finally, Covestor Ltd increased its holdings in LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.